MX2012013642A - Composiciones farmaceuticas topicas que comprenden furoato de mometasona. - Google Patents

Composiciones farmaceuticas topicas que comprenden furoato de mometasona.

Info

Publication number
MX2012013642A
MX2012013642A MX2012013642A MX2012013642A MX2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
mometasone furoate
topical pharmaceutical
skin
compositions
Prior art date
Application number
MX2012013642A
Other languages
English (en)
Inventor
Fritjof Evers
Henning Mallwitz
Ricarda Meyer
Christoph Willers
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2012013642A publication Critical patent/MX2012013642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas tópicas que comprenden, en base al peso total de la composición: a) 0.01 a 0.2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua, y d) 25 a 70% en peso de una fase oleosa; dichas composiciones son estables y se pueden aplicar de modo sencillo y seguro a grandes superficies de piel de modo aceptable por los pacientes en general, para el tratamiento o la prevención de psoriasis, dermatitis atópica (eczema atópico) y otros trastornos o enfermedades de la piel.
MX2012013642A 2010-05-26 2011-05-13 Composiciones farmaceuticas topicas que comprenden furoato de mometasona. MX2012013642A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382146A EP2394653A1 (en) 2010-05-26 2010-05-26 Topical pharmaceutical compositions comprising mometasone furoate
US36505010P 2010-07-16 2010-07-16
PCT/EP2011/002369 WO2011147536A2 (en) 2010-05-26 2011-05-13 Topical pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2012013642A true MX2012013642A (es) 2013-05-06

Family

ID=42797321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013642A MX2012013642A (es) 2010-05-26 2011-05-13 Composiciones farmaceuticas topicas que comprenden furoato de mometasona.

Country Status (33)

Country Link
US (2) US20140200203A1 (es)
EP (2) EP2394653A1 (es)
JP (1) JP5743241B2 (es)
KR (1) KR101790371B1 (es)
CN (1) CN102883725B (es)
AR (1) AR081765A1 (es)
AU (1) AU2011257586B2 (es)
BR (1) BR112012030006A2 (es)
CA (1) CA2794553C (es)
CL (1) CL2012003282A1 (es)
CO (1) CO6640244A2 (es)
DK (1) DK2575822T3 (es)
EA (1) EA022967B1 (es)
ES (1) ES2595250T3 (es)
HK (1) HK1177893A1 (es)
HR (1) HRP20161288T1 (es)
HU (1) HUE029818T2 (es)
IL (1) IL222163B (es)
LT (1) LT2575822T (es)
ME (1) ME02555B (es)
MX (1) MX2012013642A (es)
MY (1) MY160377A (es)
NZ (1) NZ602730A (es)
PL (1) PL2575822T3 (es)
PT (1) PT2575822T (es)
RS (1) RS55233B1 (es)
SG (2) SG184405A1 (es)
SI (1) SI2575822T1 (es)
SM (1) SMT201600342B (es)
TW (1) TWI473615B (es)
UY (1) UY33404A (es)
WO (1) WO2011147536A2 (es)
ZA (1) ZA201208420B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
CN105392473B (zh) * 2013-07-11 2018-06-08 宝丽制药股份有限公司 使用时产生泡沫状态的外用组合物
GB2540764A (en) * 2015-07-24 2017-02-01 Fontus Health Ltd Topical composition
CA3061238A1 (en) * 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
EP3492068A1 (en) * 2017-12-01 2019-06-05 NCP NewCare Products GmbH Composition for treating onychomycosis
US20210322585A1 (en) * 2020-04-21 2021-10-21 Deloren E. Anderson Silver titanium dioxide coating material, atomized silver titanium dioxide solution for inhaling and photocatalytic titanium dioxide solution for tattoo removal
CN114767630A (zh) * 2022-06-06 2022-07-22 黑龙江中医药大学 一种治疗变应性鼻炎的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808610A (en) 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
EP0735885B1 (en) 1993-12-21 2004-07-28 Schering Corporation Ointments comprising mometasone furoate and salicylic acid for the topical treatment of psoriasis
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
DE69804998T2 (de) 1997-10-09 2002-12-12 Schering Corp., Kenilworth Mometasonfuroat-suspensionen zum zerstäuben
TR200201343A2 (tr) 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
US7312207B2 (en) 2003-05-23 2007-12-25 Taro Pharmaceuticals North America, Inc. Topical steroid cream formulations
DE102006034883A1 (de) 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
WO2008126076A2 (en) 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate

Also Published As

Publication number Publication date
PT2575822T (pt) 2016-10-06
WO2011147536A2 (en) 2011-12-01
KR20130086137A (ko) 2013-07-31
LT2575822T (lt) 2016-10-10
CA2794553C (en) 2018-01-02
SG10201502252YA (en) 2015-05-28
ES2595250T3 (es) 2016-12-28
EP2575822B1 (en) 2016-07-06
MY160377A (en) 2017-03-15
CO6640244A2 (es) 2013-03-22
SI2575822T1 (sl) 2016-11-30
JP5743241B2 (ja) 2015-07-01
DK2575822T3 (en) 2016-10-17
AR081765A1 (es) 2012-10-17
BR112012030006A2 (pt) 2016-08-02
HRP20161288T1 (hr) 2016-11-18
CN102883725A (zh) 2013-01-16
JP2013530149A (ja) 2013-07-25
ZA201208420B (en) 2013-09-25
TWI473615B (zh) 2015-02-21
AU2011257586B2 (en) 2014-04-17
SMT201600342B (it) 2017-01-10
PL2575822T3 (pl) 2017-01-31
CL2012003282A1 (es) 2013-01-25
UY33404A (es) 2011-12-01
EP2394653A1 (en) 2011-12-14
AU2011257586A1 (en) 2012-11-01
NZ602730A (en) 2014-03-28
US20140200203A1 (en) 2014-07-17
KR101790371B1 (ko) 2017-10-25
WO2011147536A3 (en) 2012-06-07
EA201291335A1 (ru) 2013-04-30
HUE029818T2 (en) 2017-04-28
CA2794553A1 (en) 2011-12-01
TW201204367A (en) 2012-02-01
IL222163B (en) 2018-01-31
US9907807B2 (en) 2018-03-06
SG184405A1 (en) 2012-11-29
EA022967B1 (ru) 2016-03-31
EP2575822A2 (en) 2013-04-10
RS55233B1 (sr) 2017-02-28
HK1177893A1 (zh) 2013-08-30
US20160038512A1 (en) 2016-02-11
CN102883725B (zh) 2015-04-01
ME02555B (me) 2017-02-20

Similar Documents

Publication Publication Date Title
MX2012013642A (es) Composiciones farmaceuticas topicas que comprenden furoato de mometasona.
MX2020012595A (es) Composiciones farmaceuticas topicas.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
WO2011156030A3 (en) High oil-content emollient aerosol foam compositions
WO2012085523A3 (en) Skin sanitizer compositions comprising alcohol based emulsion
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MX2015003239A (es) Composiciones topicas y metodos de uso.
WO2011117377A3 (en) Compositions comprising brimonidine for the treatment of erythema
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
MX2012001686A (es) Complejo aclarador de la piel, uso del complejo, composicion cosmetica o farmaceutica que comprende el complejo y metodo para su aplicacion.
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
MX2012013607A (es) Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias.
WO2013190542A3 (en) Topical compositions for the treatment of chronic inflammatory skin disease
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
MY170724A (en) Use of certain trioxygenated benzene derivatives in body fat management
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
WO2012172218A3 (fr) Complexe d'extraits végétaux pour la protection de la peau.
GB201312583D0 (en) Combination and composition for treating obesity
TH153704A (th) องค์ประกอบทางเภสัชกรรมสำหรับใช้เฉพาะที่

Legal Events

Date Code Title Description
FG Grant or registration